Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Cost-Effectiveness of Pembrolizumab With Axitinib as First-Line Treatment for Advanced RCC
  2. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab for Advanced RCC
  3. Association Between TKI-Induced Hypertension and Treatment Outcomes in Patients With mRCC
  4. Prognostic Value of Immunological Profile Based on CD8+ and FoxP3+ T Cells for RCC
  5. Complete Response to Immune Checkpoint Inhibitor–Based Therapy in Advanced RCC
  6. Current Perspectives on Brain Metastases in Renal Cell Carcinoma
  7. Sarcopenia Is Prevalent Among Patients With mRCC Treated With Cabozantinib
  8. First-Line Systemic Therapy for mRCC
  9. First-Line Pazopanib in Poor-Risk Patients With Metastatic RCC
  10. Correlates of Clinical Benefit From Immunotherapy and Targeted Therapy in Metastatic RCC

Elsewhere

Recently Updated